Publication:
Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival

dc.contributor.authorSiriporn Keeratichamroenen_US
dc.contributor.authorKawin Leelawaten_US
dc.contributor.authorTaweesak Thongtaweeen_US
dc.contributor.authorSiriluck Narongen_US
dc.contributor.authorUmaad Aegemen_US
dc.contributor.authorSupathip Tujindaen_US
dc.contributor.authorNiphon Praditpholen_US
dc.contributor.authorRutaiwan Tohtongen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherChulabhorn Research Instituteen_US
dc.contributor.otherRajavithi Hospitalen_US
dc.contributor.otherRangsit Universityen_US
dc.date.accessioned2018-05-03T08:00:06Z
dc.date.available2018-05-03T08:00:06Z
dc.date.issued2011-10-01en_US
dc.description.abstractCholangiocarcinoma is frequently found to invade local tissues and metastasize to distal organs. We investigated the expression of CD24 in cholangiocarcinoma samples and its prognostic significance. In addition, the cellular function of CD24 was studied in the RMCCA1 cholangiocarcinoma cell line. High CD24 expression significantly correlated with lymph node metastasis and positive surgical margins in cholangiocarcinoma patients. Univariate and multivariate analyses further demonstrated that CD24 expression was significantly associated with the overall survival of these patients (p=0.007 and p=0.040, respectively). For in vitro studies, the magnetic-activated cell sorting (MACS) system was used to isolate CD24 + and CD24 - cell populations from RMCCA1 cells. CD24 + RMCCA1 cells had increased chemoresistance, adhesion (p=0.004), motility (p < 0.001), migration (p < 0.001) and invasion (p < 0.001) capabilities when compared to CD24 - cells. The matrix metalloproteinase (MMP)-7 was significantly elevated in CD24 + RMCCA1 cells (p=0.01). We found that inhibition of CD24 using siRNA silencing significantly decreased the invasive capacity of RMCCA1 cells. Both clinical and in vitro studies suggest that expression of CD24 is associated with cholangiocarcinoma disease progression. CD24 may thus serve as a new target for directed molecular therapy of cholangiocarcinoma.en_US
dc.identifier.citationInternational Journal of Oncology. Vol.39, No.4 (2011), 873-881en_US
dc.identifier.doi10.3892/ijo.2011.1088en_US
dc.identifier.issn17912423en_US
dc.identifier.issn10196439en_US
dc.identifier.other2-s2.0-79960862974en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/11462
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960862974&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleExpression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survivalen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960862974&origin=inwarden_US

Files

Collections